Axatilimab Trial
Phase 1/2
38
about 4.9 years
18+
1 site in OR
About this study
This trial is testing the safety, side effects, and effectiveness of axatilimab when combined with retifanlimab and paclitaxel for people with advanced or metastatic solid tumors. Axatilimab is a monoclonal antibody that may interfere with tumor growth and spread. Retifanlimab helps the immune system attack cancer cells, and paclitaxel stops cancer cell growth and division. This combination treatment aims to be safe, tolerable, and potentially effective in treating these cancers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Axatilimab
- 2.Receive Retifanlimab
- 3.Take Paclitaxel
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Anti-inflammatory Agent (Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors), paclitaxel (Taxane chemotherapy; stabilizes microtubules), retifanlimab
injection, intravenous
biopsy, diagnostic, imaging
Oncology